Skip to main content

Advertisement

Table 1 Clinical and cost parameter estimates for the base case and sensitivity analyses

From: Quality assurance target for community-based breast cancer screening in China: a model simulation

Parameter     Ref.
The distribution of invasive Breast Cancer stages Screen No screen Distribution [43, 44]
 Stage I 0.360 0.203 Dirichlet [15]
 Stage II 0.490 0.541
 Stage III 0.144 0.237
 Stage IV 0.006 0.019
Screen method test characteristics Sensitivity Specificity   
 CBE 0.431 (0.335–0.528) 0.994 (0.994–0.995) Uniform [15] [18]
 A series of CBE, MAM and ultrasound connection 0.330 (0.238–0.422) 0.999 (0.999–1.000)
 A series of CBE and MAM connection 0.360 (0.256–0.454) 0.999 (0.999–1.000)
Stage progression transition probabilities    [15]
 Stage I-IV 0.01 Invariant [15]
 Stage II-IV 0.08
  Stage III-IV 0.21
Compliance rate 0.5–1 Uniform [15] [18]
Attend rate 0.3–1 Uniform [15]
Transition probabilities of breast cancer(Rate per 100,000 women) All-cause mortality Breast cancer mortality  
 35- 53.86 3.78 [17]
 40- 95.25 6.90
 45- 149.34 12.66
 50- 212.43 16.57
 55- 348.31 22.74
 60- 604.84 23.49
 65- 1030.55 23.95
 70- 2036.08 25.86
 75- 3783.51 31.57
 80- 6997.94 40.36
  > 85 13,602.90 48.85
Cost componentsa Cost   
Management cost and cost for CBE $4.3   [20]
Cost of evaluating abnormal CBE
 MAM $29.0   [20]
 USG $10.2   
 Cost of biopsy $174.3   
Treatment and follow-up Treatment cost Follow-up cost  
 DCIS $1607.2 $1712.7 [21, 22]
 Stage I $1940.7 $4022.8
 Stage II $1960.1 $5653.7
 Stage III $1902.9 $6481.7
 Stage IV $1566.7 $4584.5
  1. Abbreviations: CBE; Clinical breast examination, MAM; Mammography, USG; Ultrasonography, DCIS; Ductal carcinoma in situ
  2. aExchange rate 6.8858 RMB = 1 US Dollar